Role of miR-224 in hepatocellular carcinoma: A tool for possible therapeutic intervention?

Epigenomics

Volumn 3, Issue 2, 2011, Pages 235-243

  Wang, Yu ^a   Lee, Caroline Gl ^a,b,c,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

biomarker; cancer; early detection; hepatocellular carcinoma; liver malignancies; miR 224; miRNA; prognosis

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CANCER TESTIS ANTIGEN; MICRORNA; MICRORNA 224; MICRORNA 224 INHIBITOR; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG; VORINOSTAT;

ADVANCED CANCER; APOPTOSIS; CANCER DIAGNOSIS; CANCER RISK; CANCER SURGERY; CELL DEATH; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; DNA METHYLATION; DRUG EFFICACY; DRUG TARGETING; EPIGENETICS; GENE MUTATION; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER RESECTION; NONHUMAN; PREDICTIVE VALUE; PREMEDICATION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; TUMOR GROWTH; ULTRASOUND; X CHROMOSOME;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MICRORNAS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 79955147117     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.11.5     Document Type: Review

References (52)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
2. Johnson PJ: Hepatocellular carcinoma: is current therapy really altering outcome? Gut 51, 459-462 (2002).
3. Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854 (1993). (Pubitemid 24014542)
4. Sullivan CS, Grundhoff A, Tevethia S et al.: Expression and function of microRNAs in viruses great and small. Cold Spring Harb. Symp. Quant. Biol. 71, 351-356 (2006).
5. Mallory AC,Vaucheret H: Functions of microRNAs and related small RNAs in plants. Nat. Genet. 38 Suppl, S31-S36 (2006).
6. Stefani G,Slack FJ: Small noncoding RNAs in animal development. Nat. Rev. Mol. Cell Biol. 9, 219-230 (2008). (Pubitemid 351301826)
7. Griffiths-Jones S: The microRNA Registry. Nucleic Acids Res. 32, D109-D111 (2004). (Pubitemid 38081615)
8. Griffiths-Jones S, Grocock RJ, Van Dongen S, Bateman A, Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34, D140-D144 (2006).
9. Griffiths-Jones S, Saini HK, Van Dongen S, Enright AJ: miRBase: tools for microRNA genomics. Nucleic Acids Res. 36, D154-D158 (2008). (Pubitemid 351149713)
10. Murakami Y, Yasuda T, Saigo K et al.: Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25, 2537-2545 (2006).
11. Gramantieri L, Ferracin M, Fornari F et al.: Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 67, 6092-6099 (2007). (Pubitemid 47037488)
12. Meng F, Henson R, Wehbe-Janek H et al.: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133, 647-658 (2007). (Pubitemid 47187346)
13. Huang YS, Dai Y, Yu XF et al.: Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J. Gastroenterol. Hepatol. 23, 87-94 (2008). (Pubitemid 350265207)
14. Wang Y, Lee AT, Ma JZ et al.: Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J. Biol. Chem. 283(19), 13205-13215 (2008).
15. Jiang J, Gusev Y, Aderca I et al.: Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin. Cancer Res. 14, 419-427 (2008). (Pubitemid 351226109)
16. Varnholt H, Drebber U, Schulze F et al.: MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 47, 1223-1232 (2008). (Pubitemid 351547908)
17. Ladeiro Y, Couchy G, Balabaud C et al.: MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47, 1955-1963 (2008). (Pubitemid 351952843)
18. Connolly E, Melegari M, Landgraf P et al.: Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am. J. Pathol. 173, 856-864 (2008).
19. Su H, Yang JR, Xu T et al.: MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 69, 1135-1142 (2009).
20. Huang XH, Wang Q, Chen JS et al.: Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol. Res. 39, 786-794 (2009).
21. Ura S, Honda M, Yamashita T et al.: Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49, 1098-1112 (2009).
22. Pineau P, Volinia S, Mcjunkin K et al.: miR-221 overexpression contributes to liver tumorigenesis. Proc. Natl Acad. Sci. USA 107, 264-269 (2010).
23. Wong QW, Ching AK, Chan AW et al.: MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin. Cancer Res. 16, 867-875 (2010).
24. Varnholt H: The role of microRNAs in primary liver cancer. Ann Hepatol. 7, 104-113 (2008). (Pubitemid 351845519)
25. Volinia S, Calin GA, Liu CG et al.: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103, 2257-2561 (2006).
26. Selcuklu SD, Donoghue MT, Spillane C: miR-21 as a key regulator of oncogenic processes. Biochem. Soc. Trans. 37, 918-925 (2009).
27. Galardi S, Mercatelli N, Giorda E et al.: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem. 282, 23716-24 (2007). (Pubitemid 47311902)
28. Garofalo M, Di Leva G, Romano G et al.: miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16, 498-509 (2009).
29. Esau C, Davis S, Murray SF et al.: miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3, 87-98 (2006).
30. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS: Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28, 3526-3536 (2009).
31. Xiao F, Zuo Z, Cai G et al.: miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 37, D105-D110 (2009).
32. Li Q, Wang G, Shan JL et al.: MicroRNA-224 is upregulated in HepG2 cells and involved in cellular migration and invasion. J. Gastroenterol. Hepatol. 25, 164-171 (2010).
33. Yao G, Yin M, Lian J et al.: MicroRNA-224 is involved in transforming growth factor-β-mediated mouse granulosa cell proliferation and granulosa cell function by targeting Smad4. Mol. Endocrinol. 24, 540-551 (2010).
34. Lowe SW, Lin AW: Apoptosis in cancer. Carcinogenesis 21, 485-495 (2000). (Pubitemid 30137934)
35. Evan G, Littlewood T: A matter of life and cell death. Science 281, 1317-1322 (1998). (Pubitemid 28406818)
36. Hsu PP, Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell 134, 703-7 (2008).
37. Chiaradonna F, Sacco E, Manzoni R et al.: Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene 25, 5391-5404 (2006). (Pubitemid 44330282)
38. Dang CV: MYC, microRNAs and glutamine addiction in cancers. Cell Cycle 8, 3243-3245 (2009).
39. Li X, Shen Y, Ichikawa H, Antes T, Goldberg GS: Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration. Oncogene 28, 4272-4283 (2009).
40. Wang Y, Lu Y, Toh ST et al.: Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J. Hepatol. 53, 57-66 (2010).
41. Sanlaville D, Schluth-Bolard C, Turleau C: Distal Xq duplication and functional Xq disomy. Orphanet. J. Rare Dis. 4, 4 (2009).
42. Ramocki MB, Tavyev YJ, Peters SU: The MECP2 duplication syndrome. Am. J. Med. Genet. A. 152A, 1079-1088 (2010).
43. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5, 615-625 (2005).
44. Wurmbach E, Chen YB, Khitrov G et al.: Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 45, 938-947 (2007). (Pubitemid 46646500)
45. Fu XY, Wang HY, Tan L et al.: Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. World J. Gastroenterol. 8, 638-643 (2002). (Pubitemid 34918655)
46. Zhu L, Ye Z, Cheng K, Miller DD, Mahato RI: Site-specific delivery of oligonucleotides to hepatocytes after systemic administration. Bioconjug. Chem. 19, 290-298 (2008). (Pubitemid 351213861)
47. Hrzenjak A, Moinfar F, Kremser ML et al.: Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol. Cancer 9, 49 (2010).
48. Steel LF, Shumpert D, Trotter M et al.: A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 3, 601-609 (2003). (Pubitemid 36570251)
49. Gilad S, Meiri E, Yogev Y et al.: Serum microRNAs are promising novel biomarkers. PLoS ONE 3, e3148 (2008).
50. Wang Y, Lee CG: MicroRNA and cancer - focus on apoptosis. J. Cell Mol. Med. 13, 12-23 (2009).
51. He H, Jazdzewski K, Li W et al.: The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl Acad. Sci. USA 102, 19075-19080 (2005). (Pubitemid 43049568)
52. Gui J, Tian Y, Wen X et al.: Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin. Sci. 120(5), 183-193 (2010).